Beijing Changmugu Medical Technology Co., Ltd. (referred to as 'Changmugu'), a leading provider of integrated intelligent surgical solutions for orthopedics, announced the closing of a RMB 540 million Series B financing. The funding was jointly led by CICC Capital, IDG Capital, and Venture Growth Capital, with continued follow-up investment from existing shareholder BioVenture. The proceeds from this round will primarily be used to accelerate the research and development of new orthopedic artificial intelligence and surgical robots, clinical registration, production expansion, and global market promotion."

CEC Capital served as the exclusive financial advisor in this transaction.

Over the past year, Changmugu has raised a total of RMB 660 million in financing, establishing it the largest and most prominent player in the field of orthopedic intelligence financing in 2021.

Changmugu, established in 2018 and headquartered in the Beijing Economic Techonological Development Area, is a leading Chinese provider of orthopedic intelligent surgical integrated solutions. Changmugu focuses on the research and development of orthopedic artificial intelligence and digital systems, providing intelligent surgical integrated solutions for orthopedic departments in hospitals, including AI-assisted diagnosis, personalized surgical planning, surgical robots, and post-operative evaluations.